Liposarcoma
Conference Coverage
Predicting treatment response in leiomyosarcoma, liposarcoma
Aberrations in oncogenic pathways and immune modulation influence treatment response in patients with metastatic leiomyosarcoma or liposarcoma.
Conference Coverage
SEAL: Selinexor extends PFS in advanced dedifferentiated liposarcoma
The statistical significance of the improvements varied depending on how progression-free survival was measured.
News
Trabectedin bests supportive care in advanced soft-tissue sarcomas
CHICAGO – The benefit of trabectedin vs. best supportive care was entirely in patients with leiomyosarcoma or liposarcoma.
Conference Coverage
SARCO24: Regorafenib falls short for treatment-refractory liposarcoma
Regorafenib fell short of improving progression-free survival in patients with treatment-refractory liposarcomas, Richard Reidel, MD, of Duke...
Journal Club
Sarcoma dominance in uterine carcinosarcomas linked to decreased survival
Original Research
Onodera’s Prognostic Nutritional Index in soft tissue sarcoma patients as a predictor of wound complications
Background The ability to predict a wound complication after radiation therapy and surgery for soft tissue sarcomas remains difficult....
Reviews
Soft Tissue Sarcoma: Diagnosis and Treatment
IntroductionSoft tissue sarcomas (STSs) are rare adult tumors, with 3.4 new cases per 100,000 persons or 12,310 expected new cases in 2016.1...
From the Journals
Eribulin superior to dacarbazine in advanced liposarcoma
Overall survival with eribulin was 15.6 versus 8.4 months with dacarbazine in a phase 3 randomized trial of 452 patients with advanced liposarcoma...